Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme

Hypertension Research

Volumn 29, Issue 11, 2006, Pages 865-874

  Agata, Jun ^a   Ura, Nobuyuki ^a   Yoshida, Hideaki ^a   Shinshi, Yasuyuki ^a   Sasaki, Haruki ^a   Hyakkoku, Masaya ^a   Taniguchi, Shinya ^a   Shimamoto, Kazuaki ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiotensin II; Angiotensin (1 7); Angiotensin converting enzyme 2; Olmesartan

Indexed keywords

ANGIOTENSIN ANTAGONIST; ANGIOTENSIN II; ANGIOTENSIN II [1-7] [7 ALANINE]; ANGIOTENSIN RECEPTOR; ANGIOTENSIN[1-7]; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE 2; NITRATE; NITRIC OXIDE; NITRITE; OLMESARTAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; DRUG MECHANISM; ENZYME INHIBITION; GENE OVEREXPRESSION; HEART LEFT VENTRICLE; HEART PROTECTION; HEART VENTRICLE REMODELING; HEART WEIGHT; HISTOLOGY; HYPERTENSION; MALE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; STRAIN DIFFERENCE; STROKE PRONE SPONTANEOUSLY HYPERTENSIVE RAT; WISTAR KYOTO RAT;

ALDOSTERONE; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BLOOD PRESSURE; GENE EXPRESSION; IMIDAZOLES; MALE; MYOCARDIUM; NITRATES; NITRITES; PEPTIDE FRAGMENTS; PEPTIDYL-DIPEPTIDASE A; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RENIN; TETRAZOLES; VENTRICULAR REMODELING;

EID: 33846043074     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.29.865     Document Type: Article

References (37)

1. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ: A human homolog of angiotensin converting enzyme. Cloning and functional expression as a captoprilinsensitive carboxypeptidase. J Biol Chem 2000; 275: 33238-33243.
2. Donoghue M, Hsieh F, Baronas E, et al: A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000; 87: e1-e9.
3. Ferrario CM, Chappell MC, Tallant EA, Brosnihan KB, Diz DI: Counterregulatory actions of angiotensin-(1-7). Hypertension 1997; 30: 535-541.
4. Loot AE, Roks AJ, Henning RH, et al: Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats. Circulation 2002; 105: 1548-1550.
5. Brosnihihan KB, Li P, Ferrario CM: Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension 1996; 27: 523-528.
6. Roks AJM, van Gee] PP, Pinto YM, et al: Angiotensin-(1-7) is a modulator of the human renin-angiotensin system. Hypertension 1999; 34: 296-301.
7. Ueda S, Masumori-Maemoto S, Ashino K, et al: Angiotensin-(1-7) attenuates vasoconstriction evoked by angiotensin II but not by noradrenaline in man. Hypertenison 2000; 35: 998-1001.
8. Gorelik G, Carbini LA, Scicli AG: Angiotensin-(1-7) induces bradykinin-mediated relaxation in porcine coronary artery. J Pharmacol Exp Ther 1998; 286: 403-410.
9. Deddish PA, Marcic B, Jackman HL, Wang H-Z, Skidgel RA, Erdos EG: N-domain-specific substrate and C-domain inhibitors of angiotensin-converting enzyme: angiotenisn-(1-7) and keto-ACE. Hypertension 1998; 31: 912-917.
10. Minshall RD, Tan F, Nakamura F, et al: Potentiation of the actions of bradykinin by angiotensin B2 recoptors and angiotensin-converting enzyme in CHO cells. Circ Res 1997; 81: 848-856.
11. Benzing T, Fleming I, Blaukat A, Muller-Esterl W, Busse R: Angiotensin-converting enzyme inhibitor ramiprilat interferes with the sequenstration of the B2 kinin receptor within the plasma membrane of native endothelial cells. Circulation 1999; 99: 2034-2040.
12. Danser AHJ, Tom B, de Vries R, Saxena PR: L-NAME-resistant bradykinin-induced relaxation in porcine coronary arteries is NO-dependent: effect of ACE inhibition. Br J Pharmacol 2000; 131: 195-202.
13. Ichikawa S, Takayama Y: Long-term effects of olmesartan, an Ang II receptor antagonist, on blood pressure and the renin-angiotensin-aldosterone system in hypertensive patients. Hypertens Res 2001; 24: 641-646.
14. Gavras I, Gavras H, Eprosartan Multinational Study Group: Effects of eprosartan versus enalapril in hypertensive patitents on the renin-angiotensin-aldosterone and safety parameters: results from a 26-week, double-blind, multicentre study. Curr Med Res Opin 1999; 15: 15-24.
15. Grossman E, Peleg E, Carroll J, Shamiss A, Rosenthal T: Hemodynamic and humoral effects of the angiotensin II antagonist losartan in essentioal hypertension. Am J Hypertens 1994; 7: 1041-1044.
16. Bouer IH, Reams GP, Wu Z, Lau-Sieckman A: Effects of losartan on the renin-angiotensin-aldosterone axis in essential hypertension. J Hum Hypertens 1995; 9: 237-243.
17. Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, Ferrario CM: Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension 2004; 43: 970-976.
18. Tom B, de Vries R, Saxena PR, Danser AHJ: Bradykinin potentiation by angiotensin-(1-7) and ACE inhibitors correlates with ACE C- and N-domain blockade. Hypertension 2001; 38: 95-99.
19. Benter IF, Ferrario CM, Morris M, Diz DI: Antihypertensive actions of angiotensin-(1-7) in spontaneously hypertensive rats. Am J Physiol 1995; 269: H313-H319.
20. Widdop RE, Sampey DB, Jarrott B: Cardiovascular effects of angiotenisn-(1-7) in conscious spontaneously hypertensive rats. Hypertension 1999; 34: 964-968.
21. Kobayashi N, Nishikimi T, Horinaka S, Ishimitsu T, Matsuoka H: Effects of imidapril on NOS expression and myocardial remodeling in failing heart of Dahl-salt sensitive hypertensive rats. Cardiovasc Res 1999; 44: 518-526.
22. Kobayashi N, Horinaka S, Mita S, et al: Aminoguanidine inhibits mitogen-activated protein kinase and improves cardiac performance and cardiovascular remodeling in failing hearts of salt-sensitive hypertensive rats. J Hypertens 2002; 20:2475-2485.
23. Turner AJ, Tipnis SR, Guy JL, Rice G, Hooper NM: ACEH/ACE2 is a novel mammalian metallocarboxypeptidase and a monologue of angiotensin-converting enzyme insensitive to ACE inhibitors. Can J Physiol Pharmacol 2002; 80: 346-353.
24. Turner AJ, Hooper NM: The angiotensin-converting enzyme gene family: genomics and pharmacology. Trends Pharmacol Sci 2002; 23: 177-183.
25. Crackower MA, Sarao R, Oudit GY, et al: Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 2002; 417: 822-828.
26. Vickers C, Hales P, Kaushik V, et al: Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem 2002; 277: 14838-14843.
27. Gallagher PE, Chappell MC, Bernish WB, Tallant EA: ACE2 expression in brain: angiotensin II down-regulates ACE2 in astrocytes. Hypertension 2003; 42: 389.
28. Pool JL, Glazer R, Chiang YT, Gatlin M: Dose-response efficacy of valsartan, a new angiotensin II receptor blocker. J Hum Hypertens 1999; 13: 275-281.
29. Fogari R, Mugellini A, Zoppi A, et al: Efficacy of losartan, valsartan, and telmisartan in patients with mild to moderate hypertension: a double-blind, placebo-controlled, crossover study using ambulatory blood pressure monitoring. Curr Ther Res Clin Exp 2002; 63: 1-14.
30. Mendes AC, Ferreira AJ, Pinheiro SV, Santos RA: Chronic infusion of angiotensin-(1-7) reduces heart angiotensin II levels in rats. Regul Pept 2005; 125: 29-34.
31. Walters PE, Gaspari TA, Widdop RE: Angiotensin-(1-7) acts as a vasodepressor agent via angiotensin II type 2 receptors in conscious rats. Hypertension 2005; 45: 960-966.
32. Agata J, Chao L, Chao J: Kallikrein gene delivery improves cardiac reserve and attenuates remodeling after myocardial infarction. Hypertension 2002; 40: 653-659.
33. Santos RA, Simoes e Silva AC, Marie C, et al: Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Nat Acad Sci U S A 2003; 100: 8258-8263.
34. Taliant EA, Chappell MC, Ferrario CM, Gallagher PE: Inhibition of MAP kinase activity by angiotensin-(1-7) in vascular smooth muscle cells in mediated by the Mas receptor. Hypertension 2004; 43: 1348 (Abstract).
35. Strawn WB, Ferrario CM, Tallant EA: Angiotensin-(1-7) reduces smooth muscle growth after vascular injury. Hypertension 1999; 33: 207-211.
36. Ferreira AJ, Santos RAS, Almeida AP: Angiotensin-(1-7): cardioprotective effect in myocardial ischemia/reperfusion. Hypertension 2001; 38: 665-668.
37. Averill DB, Ishiyama Y, Chappell MC, Ferrario CM: Cardiac angiotensin-(1-7) in ischemic cardiomyopathy. Circulation 2003; 108: 2141-2146.